ShangPharma Corp Stock Downgraded (SHP)

NEW YORK ( TheStreet) -- ShangPharma (NYSE: SHP) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally disappointing historical performance in the stock itself and poor profit margins.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Life Sciences Tools & Services industry average. The net income has decreased by 15.2% when compared to the same quarter one year ago, dropping from $2.55 million to $2.16 million.
  • Looking at the price performance of SHP's shares over the past 12 months, there is not much good news to report: the stock is down 43.34%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
  • The gross profit margin for SHANGPHARMA CORP -ADR is currently lower than what is desirable, coming in at 32.70%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.10% trails the industry average.
  • When compared to other companies in the Life Sciences Tools & Services industry and the overall market, SHANGPHARMA CORP -ADR's return on equity is below that of both the industry average and the S&P 500.
  • SHANGPHARMA CORP -ADR's earnings per share declined by 14.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SHANGPHARMA CORP -ADR increased its bottom line by earning $0.60 versus $0.33 in the prior year. This year, the market expects an improvement in earnings ($0.86 versus $0.60).

ShangPharma Corporation, through its subsidiaries, operates as a pharmaceutical and biotechnology research and development outsourcing company. The company has a P/E ratio of 2.1, below the average drugs industry P/E ratio of 11.1 and below the S&P 500 P/E ratio of 17.7. ShangPharma has a market cap of $111.8 million and is part of the health care sector and drugs industry. Shares are down 15.8% year to date as of the close of trading on Monday.

You can view the full ShangPharma Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

European Stocks Rise As Geopolitics Fall Away And Airlines Soar

London Gets BoE Boost but Earnings Weigh Elsewhere

Shire Surges on Baxalta Synergies and Strong Earnings Momentum

Handful of Earnings Drive European Stocks Higher

Europe Stocks Slip as Economic Data and Politics Return to the Fore